Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
RCC incidence rates stabilize while mortality rates drop
Saad AM et al. Clin Genitourin Cancer. 2018. doi: 10.1016/j.clgc.2018.10.002.
Key clinical point: In recent years, renal cell carcinoma incidence rates have stabilized, while mortality due to the disease has dropped sharply.
Major finding: Mortality rates increased from 1992 and peaked in 2001, at which point they started to drop at an ever accelerating pace, culminating in an annual percent decrease of 32.2% in the 2013-2015 time period.
Study details: Analysis including more than 104,000 patients with an RCC diagnosis in the Surveillance, Epidemiology and End Results (SEER) database from 1992 to 2015.
Disclosures: Support for the study came from the National Cancer Institute and the Department of Defense. Study authors declared that they had no conflicts of interest.
Saad AM et al. Clin Genitourin Cancer. 2018. doi: 10.1016/j.clgc.2018.10.002.